Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Marius Ardeleanu's publication output changed over time?
ScholarIQpublication output · 2014–2024
Output grew0% over the shown period — from 1 works in 2014 to 1 in 2024.
1
1
2
1
4
1
1
2014201520162018201920212024
What are the most-cited papers on Marius Ardeleanu?
ScholarIQmost cited works
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky, Lisa A. Beck, Andrew Blauvelt, Michael J. Cork, Jonathan I. Silverberg, Mette Deleuran, Yoko Kataoka, J.‐P. Lacour, Külli Kingo, Margitta Worm, Yves Poulin, Andreas Wollenberg, Yuhwen Soo, Neil M.H. Graham, Gianluca Pirozzi, Bolanle Akinlade, Heribert Staudinger, Vera Mastey, Laurent Eckert, Abhijit Gadkari, Neil Stahl, George D. Yancopoulos, Marius Ardeleanu
New England Journal of Medicine. 20162,067 CitationsOPEN ACCESS
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck, Diamant Thaçi, Jennifer D. Hamilton, Neil M.H. Graham, Thomas Bieber, Ross E. Rocklin, Jeffrey E. Ming, Haobo Ren, Richard Kao, Eric L. Simpson, Marius Ardeleanu, Steven P. Weinstein, Gianluca Pirozzi, Emma Guttman‐Yassky, Mayte Suárez‐Fariñas, Melissa Hager, Neil Stahl, George D. Yancopoulos, Allen Radin
New England Journal of Medicine. 20141,414 Citations
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Emma Guttman‐Yassky, Robert Bissonnette, Benjamin Ungar, Mayte Suárez‐Fariñas, Marius Ardeleanu, Hitokazu Esaki, Maria Suprun, Yeriel Estrada, Hui Xu, Xiangyu Peng, Jonathan I. Silverberg, Alan Menter, James G. Krueger, Rick Zhang, Usman Chaudhry, Brian N. Swanson, Neil M.H. Graham, Gianluca Pirozzi, George D. Yancopoulos, Jennifer D. Hamilton
Journal of Allergy and Clinical Immunology. 2018691 CitationsOPEN ACCESS
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Diamant Thaçi, Eric L. Simpson, Lisa A. Beck, Thomas Bieber, Andrew Blauvelt, Kim Papp, Weily Soong, Margitta Worm, Jacek C. Szepietowski, Howard Sofen, Makoto Kawashima, Richard Wu, Steven P. Weinstein, Neil M.H. Graham, Gianluca Pirozzi, Ariel Teper, E. Rand Sutherland, Vera Mastey, Neil Stahl, George D. Yancopoulos, Marius Ardeleanu
The Lancet. 2015568 Citations
Conjunctivitis in dupilumab clinical trials
Bolanle Akinlade, Emma Guttman‐Yassky, Marjolein de Bruin‐Weller, Eric L. Simpson, Andrew Blauvelt, Michael J. Cork, Errol P. Prens, Penny A. Asbell, Esen K. Akpek, Jonathan Corren, Claus Bachert, Ikuo Hirano, Jonathan Weyne, Andrew Korotzer, Z. Chen, Thomas Hultsch, Xiaoping Zhu, John D. Davis, Leda Mannent, Jennifer D. Hamilton, Ariel Teper, Heribert Staudinger, E. Rizova, Gianluca Pirozzi, Neil M.H. Graham, Brad Shumel, Marius Ardeleanu, Andreas Wollenberg
British Journal of Dermatology. 2019423 CitationsOPEN ACCESS
Related on ScholarIQ
Regeneron (United States)
Institution
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Paper
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Paper
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Paper
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Paper
Conjunctivitis in dupilumab clinical trials
Paper